

Reduced incidence of relapse and graft-versus-host disease in acute myeloid leukemia after allogeneic hematopoietic cell transplantation

Haesook T. Kim,¹ Robert J. Soiffer,² Corey Cutler,² John Koreth,² Sarah Nikiforow,² Roman M. Shapiro,² Amar Kelkar,² Mahasweta Gooptu,² Rizwan Romee,² Catherine J. Wu,² Joseph H. Antin,² Jerome Ritz² and Vincent T Ho²

¹Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, and ²Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Correspondence: H. T. Kim
htkimc@jimmy.harvard.edu

Received: January 15, 2025.
Accepted: April 2, 2025.
Early view: April 10, 2025.

<https://doi.org/10.3324/haematol.2025.287390>

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license



Supplementary Appendix

Table of Contents:	Page
Statistical Analysis	2-3
Supplementary Table 1	4
Supplementary Table 2	5 - 6
Supplementary Table 3	7
Supplementary Table 4	8
Supplementary Table 5	9
Supplementary Table 6	10
Supplementary Figure 1	11
Supplementary Figure 2	12
Supplementary Figure 3	13

Statistical Analysis

Baseline, disease and transplant characteristics were reported descriptively and compared using χ^2 test or Wilcoxon rank-sum test, as appropriate. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) whereas cumulative incidence of relapse, non-relapse mortality (NRM), and graft-versus-host disease (GVHD) were estimated in the context of a competing-risks framework. In this analysis, NRM and relapse were treated as a competing event to each other, death or relapse without developing GVHD served as a competing event for GVHD. The log-rank test and Gray test (1) were used for group comparison of PFS and OS and cumulative incidences of NRM, relapse, and GVHD, respectively. All time-to-events were measured from first day of stem cell infusion to the respective event(s). To assess the effect of year of alloHCT on outcomes in the presence of other risk factors, multivariable regression analysis was performed using Cox model for OS and PFS and the Fine and Gray model (2) for NRM, relapse and GVHD. Factors considered in multivariable analysis included age, sex, male patient with female donor, Karnofsky performance score (KPS), disease type, disease status, time from diagnosis to transplant, CMV serologic status, HCT comorbidity index (HCT-CI), cytogenetic risk at transplant according to the European Leukemia Net 2022 criteria (3), conditioning intensity, HLA type, graft source and GVHD prophylaxis. To circumvent the collinearity issue between year of transplant (2010-2016 vs 2017-2022), GVHD prophylaxis, HLA type and conditioning regimens, separate multivariable models were constructed for these factors. A category for missing data was included in multivariable model. Prior to modeling, linearity assumption for continuous variables and the proportional hazards assumption were examined. Age cutoff of 60 was used as previously defined. (4) Year of transplant was non-linear and a cutoff year (2017) was assessed using the methods of restricted cubic spline function on log relative hazard (5) and classification and regression tree for survival data (6,7). Since there were some shifts in a few baseline factors between two time periods, interactions between year of transplant and these factors were examined. All P-values were two-sided at a significance level

of 0.05 and multiplicity was not considered. All calculations were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC) and R version 4.3.2.

REFERENCES

1. Gray RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. *The Annals of Statistics*. 1988;16(3):1141-1154.
2. Fine JP and Gray RJ, A Proportional Hazards Model for the Subdistribution of a Competing Risk. *Journal of the American Statistical Association*. 1999;94(446):496-509.
3. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H., et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*. 2022;140(12):1345-1377
4. Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, Gooptu M, et al. Comparison of older related versus younger unrelated donors for old recipients of allogeneic hematopoietic cell transplantation with AML or MDS - a large single center analysis. *Transplantation and Cellular Therapy*. 2024. *Transplant Cell Ther*. 2024;30(7):687.
5. Harrell FE (2001). *Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis*. Springer.
6. Breiman L., Friedman J. H., Olshen R. A., and Stone, C. J. (1984) *Classification and Regression Trees*. Wadsworth
7. T.M Therneau and E.J Atkinson. An introduction to recursive partitioning using the rpart routines. *Division of Biostatistics* 61, Mayo Clinic, 1997.

Supplementary Table 1. Clinical Outcomes. (A) For the entire cohort. Three-year estimates of cumulative incidence of relapse and NRM, PFS and OS. Cumulative incidence of grade II-IV acute GVHD and grade III-IV acute GVHD at 6 months. Cumulative incidence of chronic GVHD and moderate-severe chronic GVHD at 2-years. B) For patients in the first complete remission only. Three-year estimates of cumulative incidence of relapse and NRM, PFS and OS. Log-rank test was used for group comparison of PFS and OS. Gray test was used for the group comparison of NRM and relapse and acute and chronic GVHD.

A. Entire Cohort: 2010-2022

		3-year estimates (95% CI)			
year HCT	N	Relapse	NRM	PFS	OS
2010-2016	612	48% (44, 52)	11% (8.6, 14)	41% (37, 45)	47% (43, 51)
2027-2022	557	36% (32, 40)	11% (8.6, 14)	53% (49, 57)	62% (57, 66)
p-value		<0.0001	0.48	<0.0001	<0.0001

		6-month estimates (95% CI)		2-year estimates (95% CI)	
year HCT	N	Gr 2-4 aGVHD	Gr 3-4 aGVHD	cGVHD	mod-sev cGVHD
2010-2016	612	25% (22, 28)	11% (8.3, 13)	43% (39, 47)	28% (25, 32)
2027-2022	557	16% (13, 20)	5% (3.4, 7)	41% (37, 45)	25% (22, 29)
p-value		0.0007	0.0012	0.88	0.48

B. CR1 only

		3-year estimates (95% CI)			
year HCT	N	Relapse	NRM	PFS	OS
2010-2016	389	45% (40, 50)	10.4% (7.3, 13)	45% (40, 50)	51% (46, 56)
2027-2022	425	35% (30, 39)	10.6% (7.8, 14)	55% (50, 59)	64% (59, 68)
p-value		0.0019	0.24	0.009	0.0014

Gr: grade. 95% CI: 95% confidence interval.

Supplementary Table 2. Multivariable analysis results for (A) relapse, NRM, PFS, OS and (B) acute/chronic GVHD.

A. Relapse, NRM, PFS and OS

		Relapse				NRM				PFS				OS			
		sHR	95% CI	p-val		sHR	95% CI	p-val		HR	95% CI	p-val		HR	95% CI	p-val	
Year HCT	>=2017 vs <2017	0.63	0.53	0.77	<.0001	0.85	0.62	1.16	0.29	0.69	0.59	0.82	<.0001	0.64	0.54	0.76	<.0001
Age	>=60 vs <60	0.99	0.79	1.23	0.89	1.63	1.12	2.38	0.011	1.17	0.97	1.42	0.10	1.27	1.04	1.55	0.019
Sex mismatch	M<-F vs Oth	1.03	0.79	1.34	0.85	1.31	0.90	1.92	0.16	1.15	0.93	1.41	0.20	1.17	0.94	1.45	0.17
Sex	M vs F	1.03	0.85	1.25	0.78	1.49	1.06	2.09	0.024	1.18	1.00	1.39	0.06	1.25	1.04	1.49	0.015
AML type	s-AML vs AML	1.25	1.01	1.54	0.04	0.95	0.67	1.36	0.80	1.19	1.00	1.43	0.054	1.23	1.02	1.48	0.032
Disease status	CR>=2 vs CR1	1.18	0.85	1.62	0.33	1.24	0.77	2.01	0.38	1.25	0.97	1.62	0.09	1.17	0.89	1.53	0.27
	Rel/IF vs CR1	1.41	1.11	1.80	0.0047	1.20	0.81	1.79	0.37	1.56	1.28	1.89	<.0001	1.51	1.23	1.85	<.0001
KPS	<90 vs 90-100	1.04	0.85	1.27	0.72	1.27	0.89	1.81	0.19	1.10	0.92	1.32	0.28	1.16	0.96	1.40	0.12
pt CMV sero status	pos vs neg	0.94	0.78	1.12	0.47	1.05	0.78	1.41	0.77	0.95	0.82	1.11	0.53	0.89	0.76	1.04	0.14
HCT-CI	2-4 vs 0-1	1.07	0.88	1.31	0.50	1.24	0.88	1.73	0.22	1.18	0.99	1.40	0.07	1.27	1.06	1.53	0.01
	>=5 vs 0-1	1.16	0.89	1.51	0.28	1.96	1.31	2.93	0.001	1.59	1.29	1.98	<.0001	1.83	1.46	2.28	<.0001
Conditioning Intensity	MAC vs RIC	0.69	0.55	0.87	0.0017	1.89	1.28	2.80	0.001	0.92	0.75	1.12	0.39	0.99	0.81	1.21	0.91
Cell Source	PB vs BM	1.00	0.77	1.30	0.98	0.86	0.57	1.29	0.46	0.89	0.71	1.10	0.27	0.84	0.67	1.05	0.12
	Cord vs BM	0.65	0.35	1.19	0.16	1.60	0.62	4.08	0.33	0.73	0.45	1.20	0.22	0.78	0.46	1.31	0.35
Time from Dx to transplant	>6m vs <=6m	0.97	0.77	1.23	0.80	1.03	0.72	1.47	0.89	1.00	0.83	1.21	0.98	1.07	0.88	1.30	0.50
Cytogenetic risk	Int vs Low	1.05	0.63	1.74	0.85	2.96	1.06	8.29	0.039	1.49	0.96	2.32	0.08	1.62	0.99	2.64	0.053
	High vs Low	1.99	1.20	3.33	0.01	2.49	0.87	7.16	0.09	2.58	1.64	4.05	<.0001	2.84	1.73	4.66	<.0001
HLA type	MUD vs MRD	0.94	0.75	1.17	0.57	1.18	0.80	1.73	0.41	0.99	0.82	1.21	0.95	1.22	0.99	1.50	0.06
	Haplo vs MRD	0.51	0.34	0.78	0.0017	1.62	0.84	3.10	0.15	0.76	0.54	1.08	0.13	1.07	0.74	1.54	0.72
	Mismatch vs MRD	1.01	0.75	1.36	0.95	1.15	0.68	1.95	0.60	1.04	0.80	1.34	0.77	1.28	0.97	1.68	0.08
GVHD Prophylaxis	Tac/MTX/Sir vs Tac/MTX	1.17	0.89	1.55	0.25	1.19	0.74	1.93	0.47	1.17	0.93	1.48	0.19	1.08	0.84	1.37	0.56
	Tac/Sir vs Tac/MTX	1.07	0.81	1.41	0.64	2.05	1.38	3.05	0.0004	1.33	1.06	1.68	0.014	1.35	1.07	1.72	0.013
	PTCY vs Tac/MTX	0.68	0.50	0.92	0.013	1.14	0.67	1.92	0.63	0.86	0.66	1.12	0.26	0.90	0.68	1.19	0.44
	Other vs Tac/MTX	1.20	0.82	1.78	0.35	1.54	0.83	2.85	0.17	1.61	1.18	2.19	0.0027	1.73	1.25	2.38	0.0009

B. Acute and chronic GVHD

		Gr. II-IV acute GVHD				Gr. III-IV acute GVHD				Chronic GVHD			Mod-Severe chronic GVHD				
		sHR	95% CI		p-val	sHR	95% CI		p-val	sHR	95% CI		p-val	sHR	95% CI		p-val
Year HCT	>=2017 vs <2017	0.66	0.51	0.85	0.0012	0.51	0.33	0.79	0.0025	0.94	0.79	1.13	0.53	0.85	0.67	1.07	0.16
Age	>=60 vs <60	0.99	0.72	1.37	0.97	1.00	0.60	1.66	0.98	0.91	0.74	1.13	0.39	0.99	0.75	1.31	0.96
Sex mismatch	M<-F vs Oth	0.84	0.59	1.19	0.33	0.80	0.46	1.40	0.44	1.08	0.83	1.39	0.57	1.13	0.82	1.54	0.46
Sex	M vs F	1.38	1.05	1.80	0.02	1.60	1.04	2.46	0.034	1.02	0.85	1.24	0.81	0.95	0.75	1.22	0.69
AML type	s-AML vs AML	0.88	0.65	1.21	0.44	1.01	0.62	1.66	0.96	1.01	0.80	1.26	0.95	0.89	0.66	1.20	0.43
Disease status	CR>=2 vs CR1	1.19	0.78	1.81	0.43	0.97	0.48	1.96	0.92	0.77	0.57	1.04	0.09	0.76	0.51	1.13	0.17
	Rel/IF vs CR1	1.39	1.00	1.94	0.05	1.26	0.74	2.15	0.40	0.77	0.59	1.00	0.053	0.85	0.62	1.18	0.33
KPS	<90 vs 90-100	0.91	0.69	1.21	0.52	1.25	0.77	2.03	0.37	0.86	0.71	1.04	0.12	0.83	0.65	1.05	0.12
pt CMV sero status	pov vs neg	0.93	0.73	1.18	0.54	0.90	0.60	1.33	0.58	1.12	0.93	1.33	0.23	1.15	0.92	1.43	0.21
HCT-CI	2-4 vs 0-1	1.13	0.86	1.49	0.38	1.39	0.88	2.19	0.16	0.98	0.81	1.19	0.85	0.88	0.69	1.12	0.29
	>=5 vs 0-1	1.30	0.91	1.88	0.15	1.82	1.01	3.29	0.047	0.85	0.65	1.10	0.21	0.75	0.53	1.05	0.09
Conditioning Intensity	MAC vs RIC	1.33	0.96	1.84	0.09	1.47	0.86	2.52	0.16	1.11	0.89	1.38	0.34	1.09	0.82	1.45	0.55
Cell Source	PB vs BM	1.45	0.97	2.18	0.07	1.45	0.79	2.68	0.23	1.42	1.09	1.86	0.01	1.94	1.31	2.86	0.0008
	Cord vs BM	1.86	0.85	4.04	0.12	2.29	0.74	7.06	0.15	1.00	0.51	1.96	1.00	0.75	0.29	1.99	0.57
Time from Dx to transplant	>6m vs <=6m	0.92	0.68	1.25	0.61	1.02	0.61	1.70	0.95	1.06	0.85	1.32	0.60	1.13	0.85	1.49	0.41
Cytogenetic risk	Int vs Low	1.97	0.88	4.39	0.10	5.16	0.70	38.08	0.11	0.92	0.62	1.37	0.70	1.14	0.65	2.00	0.64
	High vs Low	2.28	1.01	5.13	0.05	4.61	0.61	35.01	0.14	0.75	0.49	1.15	0.19	0.99	0.55	1.79	0.97
HLA type	MUD vs MRD	1.16	0.83	1.60	0.39	1.00	0.59	1.71	0.99	1.11	0.89	1.38	0.36	1.28	0.97	1.69	0.08
	Haplo vs MRD	1.10	0.62	1.94	0.75	0.67	0.24	1.92	0.46	0.62	0.40	0.97	0.036	0.55	0.30	1.02	0.06
	Mismatch vs MRD	1.80	1.20	2.69	0.0044	1.45	0.78	2.72	0.24	1.04	0.77	1.42	0.79	0.95	0.64	1.42	0.80
GVHD Prophylaxis	Tac/MTX/Sir vs Tac/MTX	0.82	0.55	1.22	0.32	1.66	0.88	3.11	0.11	1.12	0.86	1.47	0.39	1.08	0.77	1.50	0.67
	Tac/Sir vs Tac/MTX	1.05	0.71	1.55	0.80	1.49	0.82	2.70	0.19	1.03	0.79	1.35	0.82	1.41	1.05	1.89	0.02
	PTCY vs Tac/MTX	0.84	0.56	1.26	0.40	0.78	0.37	1.62	0.51	0.46	0.33	0.64	<.0001	0.37	0.23	0.59	<.0001
	Other vs Tac/MTX	1.18	0.72	1.93	0.52	1.66	0.80	3.44	0.18	0.40	0.25	0.66	0.0003	0.33	0.17	0.67	0.002

sHR: subdistribution hazard ratio. M: male. F: female. M<-F: male patient with female donor. Oth: Other. s-AML: secondary AML. CR: complete remission. Rel/IF: relapse or induction failure. MAC: myeloablative conditioning. RIC: reduced conditioning. KPS: karnofsky performance score. Pt: patient. CMV sero status: cytomegalovirus serologic status. Pos: positive. Neg: negative. HCT-CI: HCT comorbidity index. PB: peripheral blood. BM:

bone marrow. 8/8 MUD: 8/8 matched unrelated donor. 8/8 MRD: 8/8 matched related donor. Tac: tacrolimus. MTX: methotrexate. Sir: sirolimus. PTCY: post-transplant cyclophosphamide

Supplementary Table 3. Interaction between year of transplant and conditioning intensity and disease status.

(A). According to conditioning intensity and year of transplant

			3-year estimates (95% CI)			
		N	Relapse	NRM	PFS	OS
RIC	<2017	304	53% (47, 58)	8.9% (6, 13)	37% (32, 43)	45% (39, 51)
	≥2017	305	39% (33, 44)	11% (7.7, 15)	50% (44, 56)	57% (51, 62)
	p-value		<0.0001	0.13	0.0009	0.0085
MAC	<2017	308	44% (38, 49)	13% (9, 17)	44% (38, 49)	49% (43, 54)
	≥2017	252	32% (26, 38)	11% (7.7, 16)	57% (50, 63)	68% (61, 73)
	p-value		0.01	0.72	0.004	<0.0001

RIC: reduced intensity conditioning. MAC: myeloablative conditioning

(B) Multivariable analysis results for conditioning regimens

		Relapse				NRM			
		sHR	95% CI		p-val	sHR	95% CI		p-val
RIC	Flu/Bu2 vs Flu/Bu1	0.74	0.51	1.07	0.11	1.11	0.57	2.15	0.77
	Flu/Mel±ATG vs Flu/Bu1	0.30	0.16	0.55	<.0001	2.30	0.95	5.58	0.07
	Flu/Cy/TBI vs Flu/Bu1	0.52	0.31	0.87	0.014	1.33	0.45	3.88	0.60
MAC	Flu/Bu4 vs Cy/TBI	1.12	0.76	1.65	0.57	0.44	0.26	0.74	0.0019
	Bu/Cy vs Cy/TBI	1.32	0.76	2.31	0.33	0.25	0.07	0.91	0.035

sHR: subdistribution hazard ratio

(C) According to disease status and year of transplant

			3-year estimates (95% CI)			
		N	Relapse	NRM	PFS	OS
CR	<2017	490	45% (41, 50)	10.6% (8,14)	44% (40, 49)	51% (47,56)
	≥2017	486	35% (30, 39)	10% (7.7,13)	55% (50, 59)	64% (59,68)
	p-value		0.001	0.58	0.0016	0.0004
No CR	<2017	122	61% (51, 69)	12% (7,19)	27% (19,34)	31% (23, 39)
	≥2017	71	43% (31, 54)	17% (9,27)	40% (29,52)	48% (36, 59)
	p-value		0.01	0.45	0.02	0.01

CR: complete remission. No CR: no complete remission

Supplementary Table 4. Effect of GVHD on relapse, NRM, PFS and OS. Multivariable Cox model was used treating acute and chronic GVHD as time dependent variables. (A) for the entire cohort (N=1169). (B) For patients transplanted since 2017 (N=557). (C) For patients who received post-transplant cyclophosphamide (PTCY) GVHD prophylaxis. For relapse and NRM, these are cause-specific hazards models.

(A) All Cohort (N=1169)

		Relapse			NRM			PFS			OS		
		HR	95%CI	p-val	HR	95%CI	p-val	HR	95%CI	p-val	HR	95%CI	p-val
aGVHD	2 vs 0-1	1.00	0.76	1.32	0.99	1.62	1.04	2.51	0.03	1.12	0.89	1.42	0.32
	3 vs 0-1	0.85	0.52	1.39	0.52	4.90	3.17	7.57	<.0001	1.74	1.27	2.37	0.0005
	4 vs 0-1	1.93	0.98	3.82	0.06	5.99	2.97	12.10	<.0001	2.96	1.86	4.72	<.0001
cGVHD	mild vs no	0.59	0.39	0.90	0.014	1.38	0.80	2.38	0.25	0.75	0.54	1.05	0.09
	mod vs no	0.43	0.27	0.67	0.0002	1.01	0.60	1.69	0.97	0.58	0.42	0.80	0.0009
	severe vs no	0.26	0.14	0.49	<.0001	2.45	1.55	3.90	0.0001	0.81	0.59	1.12	0.20

(B) >=2017 only (N=557)

		Relapse			NRM			PFS			OS		
		HR	95%CI	p-val	HR	95%CI	p-val	HR	95%CI	p-val	HR	95%CI	p-val
aGVHD	2 vs 0-1	1.14	0.81	1.62	0.45	1.59	0.88	2.89	0.13	1.21	0.90	1.63	0.21
	3 vs 0-1	0.90	0.49	1.67	0.75	10.0	5.65	17.86	<.0001	2.12	1.44	3.11	0.0001
	4 vs 0-1	1.50	0.55	4.13	0.43	9.61	3.87	23.90	<.0001	2.81	1.49	5.30	0.0014
cGVHD	mild vs no	0.50	0.30	0.82	0.0064	1.51	0.77	2.96	0.24	0.66	0.45	0.98	0.039
	mod vs no	0.32	0.18	0.56	<.0001	1.27	0.68	2.36	0.45	0.53	0.36	0.77	0.001
	severe vs no	0.24	0.11	0.52	0.0003	3.43	1.89	6.21	<.0001	0.81	0.55	1.20	0.29

(C) PTCy only (N=164)

		Relapse			NRM			PFS			OS		
		HR	95%CI	p-val	HR	95%CI	p-val	HR	95%CI	p-val	HR	95%CI	p-val
aGVHD	2 vs 0-1	2.05	0.96	4.38	0.063	1.68	0.32	8.78	0.54	1.92	0.98	3.79	0.059
	3-4 vs 0-1	0.86	0.23	3.24	0.82	10.68	1.45	78.62	0.02	1.74	0.66	4.60	0.26
cGVHD	mild vs no	0.28	0.04	2.16	0.22	1.03	0.08	12.92	0.98	0.41	0.09	1.85	0.25
	mod-sev vs no	0.52	0.12	2.34	0.40	2.68	0.23	31.29	0.43	0.70	0.20	2.45	0.58

aGVHD: acute GVHD. cGVHD: chronic GVHD.

Note: For the PTCY cohort, grade III and IV acute GVHD were combined due to a small number of events (7 grade III and 2 grade IV acute GVHD cases). Similarly moderate (N=12) and severe chronic GVHD (N=3) were combined.

Supplementary Table 5. Landmark analysis at 2 years post transplant (N=527).

Multivariable analysis to assess the effect of chronic GVHD on outcomes for long term survivors. Mild, moderate and severe chronic GVHD denote those who developed chronic GVHD within 2 years of transplant. No chronic GVHD denotes those with no history of chronic GVHD within 2 years of transplant. Cox model was used for OS and PFS and Fine and Gray model was used for NRM and relapse. sHR: subdistribution hazard ratio. HR: hazard ratio. CI: confidence interval.

	Relapse				NRM				PFS				OS			
	sHR	95% CI		p-val	sHR	95% CI		p-val	HR	95% CI		p-val	HR	95% CI		p-val
Mild vs No cGVHD	1.00	0.44	2.25	0.99	1.82	0.77	4.30	0.17	1.30	0.75	2.28	0.35	1.58	0.87	2.86	0.13
Moderate vs No cGVHD	0.57	0.23	1.41	0.22	2.25	0.99	5.08	0.052	1.11	0.65	1.90	0.71	1.20	0.66	2.16	0.55
Severe vs No cGVHD	0.44	0.18	1.11	0.08	6.73	3.01	15.06	<.0001	2.51	1.50	4.19	0.0004	2.89	1.66	5.03	0.0002

Supplementary Table 6. Post relapse survival according to year of transplant, time from transplant to relapse, HLA type and first relapse site.

Year of transplant	N	2yr post relapse survival (95% CI)	HR (95% CI)
2010-2016	314	12.6% (9, 17)	Ref
2017-2022	202	23% (17, 29)	0.61 (0.49, 0.76)
p-value		0.00003	<.0001

Months from transplant to relapse	N	2yr post relapse survival (95% CI)	HR (95% CI)
<=3m	144	5% (2.3, 9.7)	3.04 (2.25, 4.1)
3-<=6m	174	11% (6.8, 16)	2.06 (1.54, 2.76)
6-<=12m	85	24% (15, 34)	1.4 (.01, 1.96)
>12m	113	34% (25, 43)	Ref
p-value		<0.00001	<0.0001*, 0.045**


HLA type	N	2yr post relapse survival (95% CI)	HR (95% CI)
8/8 MRD	122	29% (21, 37)	Ref
No 8/8 MRD	394	12.7% (9, 16)	1.78 (1.39, 2.28)
p-value		<0.0001	<.0001

Relapse site	N ^a	2yr post relapse survival (95% CI)	HR (95% CI)
BM	433	14% (11, 18)	Ref
BM+EM	33	17% (6.7, 30)	1.39 (0.92, 2.09)
EM	47	38% (25, 55)	0.43 (0.28, 0.65)
p-value		0.0056	0.12 ^b , <0.0001 ^c


Ref: reference group. yr: year. 95% CI: 95% confidence interval.

HR: hazard ratio from multivariable Cox model for post relapse survival from date of first relapse. * for comparison between <=3m and >12m and between 3-<=6m and >12m. **: comparison between 6-<=12m and >12m. ^a: 3 patients with relapse site unavailable were excluded. ^b: for comparison between BM+EM vs BM. ^c: for comparison between EM vs BM.

Supplementary Figure 1. (A) Log relative hazard of relapse against year of transplantation. (B) Log relative hazard of PFS against year of transplantation. Cause-specific proportional hazards model was used for relapse. Solid line: estimated restricted cubic spline function relating year of transplantation to each outcome using Cox model. Dotted line: 95% confidence interval. The actual year was subtracted by 2000 for ease of visual presentation. For example, year 2022 is denoted as 22.




Supplementary Figure 2. Cumulative incidence of chronic GVHD according to PTCY use. (A) no PTCY group. (B) PTCY group. Gray test was used for group comparison.



		2-year estimates		
	N	All cGVHD	mod-sev cGVHD	Severe cGVHD
No PTCY	1005	45% (42, 48)	29% (27, 32)	12% (10, 14)
PTCY	164	25% (18, 32)	11% (6.8, 16)	1.8 % (0.5, 4.9)
p-value		<0.0001	<0.0001	<0.0001

Supplementary Figure 3. Post relapse survival according to year of transplant and conditioning intensity



	Year HCT	N	2yr OS	p-value
RIC	2010-2016	177	15% (10, 21)	0.4
	2017-2022	119	14% (8, 22)	
MAC	2010-2016	141	9% (4, 14)	<0.00001
	2017-2022	83	35% (24, 46)	